SecBot SecBot
PRESS-RELEASE ·Filed May 14, 2026

PYXS

Pyxis Oncology
NEUTRAL
Impact 4/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor upcoming MICVO data readouts (mid-2026 and 2H26) for potential catalysts; limited cash runway suggests financing risk if trials delay.

DirectionNeutral
Confidencemedium
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$2.21
T+0 close · May 14, 2026 · via day close
Latest settled
+73.30%
T+60 · $3.83
Vs SPY
+69.71%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 14 $2.21entry
  2. T+1 · 6mo ago +3.17%α +4.39% · $2.28
  3. T+5 · 6mo ago −12.22%α −11.50% · $1.94
  4. T+20 · 5mo ago −20.36%α −19.50% · $1.76
  5. T+60 · 3mo ago +73.30%α +69.71% · $3.83

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pyxis Oncology reported Q1 2026 EPS of -$0.37, missing consensus of -$0.35 by 5.7%. The clinical-stage biotech has $42.5M cash runway into Q4 2026 and reiterated MICVO Phase 1 monotherapy data for mid-2026 and combination data for 2H26. The modest earnings miss is typical for pre-revenue companies and overshadowed by pipeline milestones.

Key Financial Metrics

EPS
−$0.37
est −$0.35 · -5.7%
Revenue
$0.00
est $0.00
Rating
miss

Key Facts

  • Q1 2026 EPS -$0.37 vs consensus -$0.35 (5.7% miss)
  • Cash and investments $42.5M, runway into Q4 2026
  • MICVO Phase 1 monotherapy update expected mid-2026, combination data 2H26
  • No revenue (clinical-stage biotech)

Financial Impact

Net loss of $23.3M in Q1 2026, up from $21.2M in Q1 2025; cash burn $42.5M remaining

epscashnet loss

Risk Factors

  • Cash runway only into Q4 2026, possible dilution if milestones slip
  • Clinical trial failure risk for MICVO
  • Pre-revenue stage with no near-term revenue prospects

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
87% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3294764

Track record

25 reports on PYXS

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.94% at T+60 after the Apr 17, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.43 Now $1.41 −1.32% settles Dec 16
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.43 Now $1.41 −1.40% settles Dec 16
  3. Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.55 Now $1.41 −9.14% settles Dec 15
  4. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $1.61 Now $1.41 −12.42% settles Dec 4
  5. Nov 3, 202613d ago SC 13G/A Bearish 5/10 Entry $1.64 Now $1.41 +14.02% settles Dec 2
  6. Oct 27, 202620d ago Press Release Neutral 4/10 Entry $1.84 Now $1.41 −23.37% settles Nov 24
  7. Oct 21, 202626d ago DEF 14A Bearish 6/10 Entry $1.71 Now $1.41 +17.54% settles Nov 19
  8. Oct 9, 20265w ago SC 13G/A Neutral 4/10 Entry $2.03 to $1.66 Now $1.41 −30.54% ▼ −18.23% −12.67% vs SPY
  9. Oct 2, 20266w ago SC 13G/A Neutral 4/10 Entry $2.14 to $1.81 Now $1.41 −34.11% ▼ −15.42% −13.61% vs SPY
  10. Oct 2, 20266w ago Press Release Bearish 7/10 Entry $2.14 to $1.81 Now $1.41 +34.11% ▲ +15.42% +13.61% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 14, 2026